Pendergrass, M <br/><br/>
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Jul 2012 
 - 596-600 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/j.1463-1326.2012.01567.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Kidney Injury--chemically induced<br/>Adolescent<br/>Adult<br/>Cohort Studies<br/>Diabetes Mellitus, Type 2--complications<br/>Dipeptidyl-Peptidase IV Inhibitors--administration & dosage<br/>Drug Labeling<br/>Exenatide<br/>Female<br/>Humans<br/>Incidence<br/>Male<br/>Middle Aged<br/>Peptides--administration & dosage<br/>Proportional Hazards Models<br/>Pyrazines--administration & dosage<br/>Retrospective Studies<br/>Risk Assessment<br/>Sitagliptin Phosphate<br/>Triazoles--administration & dosage<br/>Venoms--administration & dosage<br/>Young Adult